Core Insights - Qualigen Therapeutics, Inc. is undergoing a significant transformation, transitioning from a traditional biotechnology company to a decentralized artificial intelligence technology platform under the new name AIxCrypto Holdings, Inc. [4][5][6] - Faraday Future is set to become the majority and controlling shareholder with an estimated 55% direct equity ownership, increasing to approximately 63% when including affiliated stockholders [2][10] - The company will host a renaming and ticker activation ceremony on November 20, 2025, where it will unveil its new business framework, ecosystem architecture, and a three-year development roadmap [4][7][10] Shareholder Approvals - All proposals at the Special Meeting of Stockholders were approved, confirming Faraday Future as the new majority and controlling shareholder [10] - The approved actions include the nomination of a majority of board seats by Faraday Future prior to the renaming event [10] - A subscription agreement was approved for the issuance of 337,432 common shares and 39,943 Series B convertible preferred shares [11] Strategic Transformation - The renaming signifies a strategic shift towards a Web3-driven decentralized AI technology platform, aiming to create a reciprocal strategic enablement dynamic between AIxCrypto and Faraday Future [5][6] - The company is committed to defining itself as a leading gateway to the AI × Web3 era, with a focus on decentralized AI, Web3 asset infrastructure, and intelligent trading systems [6][7][8] - The upcoming ceremony will also introduce the newly structured Board of Directors and the incoming Chairperson [4][10]

Cancer Treatment Development - The company is focused on developing treatments for adult and pediatric cancer, with one early-clinical-stage program (QN-302) and one preclinical program (Pan-RAS) [183] - QN-302 is a small molecule G-quadruplexes selective transcription inhibitor aimed at inhibiting cancer cell proliferation, particularly in pancreatic cancer [184] - The Pan-RAS program targets mutated RAS genes, potentially effective in treating approximately 25% of all cancers, including pancreatic, colorectal, and lung cancers [185] Financial Agreements and Funding - A Co-Development Agreement with Marizyme, Inc. includes a 33% royalty on net sales of DuraGraft™ after a cumulative total of $500,000 in sales, with $700,000 already provided in funding [186] - A Subscription Agreement with investors, including Faraday Future, raised $41.0 million, with $6.8 million allocated for debt repayment and business operations [191] - The company entered into a Co-Development Agreement with Marizyme, Inc., agreeing to pay up to $1.75 million in funding payments and an exclusivity fee of $200,000 [252] Profitability and Financial Performance - The company does not expect to be profitable until its therapeutic products are commercialized, leading to a slowdown in development and implementation of expense controls starting Q2 2024 [188] - The company expects to continue incurring net losses and negative cash flow from operations, raising substantial doubt regarding its ability to continue as a going concern [235] Expenses and Losses - General and administrative expenses increased from $1.1 million in Q3 2024 to $1.9 million in Q3 2025, a 72% increase, primarily due to a $1.3 million rise in professional fees [204] - Research and development expenses decreased from approximately $123,000 in Q3 2024 to approximately $105,000 in Q3 2025, a 15% decrease, mainly due to slowed R&D activities [205] - Total expenses for Q3 2025 were $1.4 million, compared to $1.3 million in Q3 2024, reflecting an increase of approximately 12.7% [203] - Net loss from continuing operations for Q3 2025 was $2.0 million, compared to a net loss of $1.8 million in Q3 2024, representing an increase of 13.5% [203] - General and administrative expenses for the nine months ended September 30, 2025, were $5.8 million, up from $3.2 million in the same period of 2024, a 78% increase [216] - Research and development expenses for the nine months ended September 30, 2025, decreased to $0.2 million from $1.2 million in 2024, an 81% decrease [217] - The loss from continuing operations for the nine months ended September 30, 2025, was $6.5 million, up from a loss of $5.3 million in the same period of 2024, reflecting a year-over-year increase of approximately 23% [256][257] Cash Flow and Financial Position - As of September 30, 2025, the company had approximately $38.8 million in cash and net accounts payable of approximately $1.3 million, with an accumulated deficit of $129.6 million [231] - The company used cash of $4.8 million and $6.4 million in operations for the nine months ended September 30, 2025, and the year ended December 31, 2024, respectively [231] - The company raised a total of $44.2 million through financing activities for the nine months ended September 30, 2025, compared to $4.9 million in the same period for 2024 [255] - Net cash used in investing activities for the nine months ended September 30, 2025, was $1.8 million due to advances to Marizyme, while in 2024, net cash provided was $900,000, indicating a significant shift of $2.7 million [258] - Net cash provided by financing activities for the nine months ended September 30, 2025, was $44.2 million, a substantial increase from approximately $4.9 million in 2024, representing an increase of over 800% [259][260] - The financing activities in 2025 included the issuance of preferred shares amounting to $38.8 million, which was a key contributor to the increase in cash provided [259] Credit and Interest - The estimated expected credit losses on the Marizyme Notes is $261,000, highlighting the uncertainty in the debtor's financial condition [199] - Credit loss expense for short-term note receivable rose from $0 in Q3 2024 to $0.6 million in Q3 2025, a 100% increase, as Marizyme notes were first recorded in July 2024 [206] - Interest income increased from approximately $48,000 in the nine months ended September 30, 2024, to $0.4 million in 2025, a significant increase due to Marizyme notes receivable [224] - The company reported a $0.4 million loss on change in fair value of warrant liabilities for the nine months ended September 30, 2025 [256] Shareholder Information - The weighted-average number of shares outstanding increased from 387,878 in Q3 2024 to 620,694 in Q3 2025 [203] - Total net loss per common share for Q3 2025 was $(4.68), slightly improved from $(4.70) in Q3 2024 [203] Miscellaneous - The company issued short-term notes payable totaling $1.0 million during the nine months ended September 30, 2025, with a penalty provision totaling $1.1 million in case of default [249] - The company repaid approximately $1.2 million to three lenders in July 2025, including a $0.2 million premium recorded under interest expense [250] - The company is classified as a smaller reporting company and is not required to provide additional market risk disclosures [261]

Core Insights - Faraday Future Intelligent Electric Inc. has made a strategic investment in Qualigen Therapeutics Inc., which will be renamed AIxCrypto after the shareholder meeting on November 12, 2025 [1][2] - The investment amounts to over $41 million, with Faraday Future contributing approximately $30 million for a 55% stake, while founder Jia Yueting invests $4 million for a 7% stake [2] - AIxCrypto plans to launch new Web3 and cryptocurrency initiatives, including the public testing of BesTrade DeAI Agent and the release of the EAI RWA Utility token white paper by the end of November [2][3] Investment Details - Faraday Future's investment is led by Jia Yueting and includes participation from Binance Labs, Sequoia Capital, IDG, and Circle [1] - After the investment, Faraday Future and Jia Yueting will collectively hold about 62% of Qualigen Therapeutics [2] Business Strategy - AIxCrypto aims to achieve three key milestones by the end of 2025: 1. Expand the asset management scale of C10 Treasury to $50 million, enhancing its role as a core reserve asset in the Web3 ecosystem [2] 2. Accelerate the global growth of BesTrade DeAI Agent, establishing it as a top AI trading platform [3] 3. Launch a Crypto ecosystem token on leading exchanges, creating a sustainable on-chain value growth system [3]

Core Insights - Qualigen Therapeutics Inc. (QLGN) will rebrand to AIxCrypto after its shareholder meeting on November 12, 2025, and has set three core objectives for 2025 [1][2] Group 1: Business Strategy - QLGN has initiated a new Web3 and cryptocurrency business plan, with the public beta of BesTrade DeAI Agent set to launch at the end of November [1][2] - The first milestone aims to expand the C10 Treasury's asset management scale to $50 million, enhancing its role as a core reserve asset in the Web3 ecosystem [1] - As of October 17, 2023, QLGN's C10 Treasury has completed a $12 million allocation in cryptocurrency assets [1] Group 2: Product Development - The second milestone focuses on accelerating the global growth of BesTrade DeAI Agent, which is designed to optimize trading paths and returns, establishing itself as a leading AI trading platform [2] - The third milestone involves launching the Crypto ecosystem Token on leading exchanges, which will consist of C10 stablecoin and EAI+Crypto products, aiming to create a sustainable on-chain value growth system [2] Group 3: Investment Details - Faraday Future Intelligent Electric Inc. (FFAI), led by founder Jia Yueting, has made a strategic investment in QLGN, with the total investment expected to exceed $41 million, subject to shareholder approval [3] - FFAI invested approximately $30 million for about 55% ownership in QLGN, while Jia Yueting personally invested around $4 million for about 7% ownership [3] - Post-investment, FFAI and Jia Yueting will collectively hold approximately 62% of QLGN, with FFAI gaining significant board representation [3]

Core Viewpoint - Qualigen Therapeutics Inc. will rebrand as AIxCrypto following its stockholder meeting on November 12, 2025, and is launching new initiatives in the Web3 and crypto asset sectors [1] Group 1: Rebranding and New Initiatives - The company will officially change its name to AIxCrypto and introduce its new business initiatives in the crypto space [1] - AIxCrypto plans to launch the public beta of its BesTrade DeAI Agent by the end of November 2025 and release its EAI RWA Utility Token Whitepaper [2] Group 2: Strategic Goals - AIxCrypto aims to expand the C10 Treasury to $50 million in assets under management (AUM), having completed $12 million in crypto asset allocations as of October 17, 2025 [2] - The company intends to accelerate global growth of the BesTrade DeAI Agent, which will serve as a Meta Exchange optimizing transaction pathways and returns [3] - AIxCrypto plans to launch crypto ecosystem tokens on leading exchanges, supported by a potential C10 stablecoin and EAI + Crypto RWA dual-bridge products [4] Group 3: Company Background - Qualigen Therapeutics, Inc. is a biotechnology company based in Carlsbad, California, focusing on innovative oncology and immunology therapies while expanding into crypto asset and Web3 strategies [5]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Click Holdings Limited (CLIK) is up 81% at $11.17 [3] - Avidity Biosciences, Inc. (RNA) is up 43% at $70.72 [3] - Dyne Therapeutics, Inc. (DYN) is up 37% at $23.58 [3] - Zenas BioPharma, Inc. (ZBIO) is up 21% at $29.00 [3] - ProPetro Holding Corp. (PUMP) is up 18% at $7.47 [3] - PepGen Inc. (PEPG) is up 17% at $5.35 [3] - Unusual Machines, Inc. (UMAC) is up 15% at $14.85 [3] - Semler Scientific, Inc. (SMLR) is up 14% at $27.32 [3] - ETHZilla Corporation (ETHZ) is up 13% at $20.51 [3] - Relmada Therapeutics, Inc. (RLMD) is up 13% at $2.38 [3] Premarket Losers - Smart Logistics Global Limited (SLGB) is down 37% at $3.21 [4] - MaxsMaking Inc. (MAMK) is down 22% at $4.08 [4] - Prenetics Global Limited (PRE) is down 14% at $14.40 [4] - United States Antimony Corporation (UAMY) is down 14% at $10.22 [4] - NeurAxis, Inc. (NRXS) is down 12% at $3.01 [4] - Obook Holdings Inc. (OWLS) is down 9% at $11.39 [4] - Qualigen Therapeutics, Inc. (QLGN) is down 9% at $3.30 [4] - Critical Metals Corp. (CRML) is down 8% at $13.70 [4] - Neuphoria Therapeutics Inc. (NEUP) is down 8% at $5.73 [4] - Beam Therapeutics Inc. (BEAM) is down 7% at $25.86 [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Qualigen Therapeutics, Inc. (QLGN) increased by 69% to $6.00 - Inhibrx Biosciences, Inc. (INBX) rose by 62% to $46.04 - MidWestOne Financial Group, Inc. (MOFG) gained 33% to $37.87 - Neuphoria Therapeutics Inc. (NEUP) up by 31% to $5.32 - Nextracker Inc. (NXT) increased by 13% to $102.44 - Avalon Holdings Corporation (AWX) rose by 11% to $2.98 - Beyond Meat, Inc. (BYND) up by 9% to $3.12 - SLM Corporation (SLM) increased by 8% to $29.00 - Reborn Coffee, Inc. (REBN) rose by 7% to $2.40 - Oriental Culture Holding LTD (OCG) increased by 5% to $3.55 [3] Premarket Losers - Picard Medical, Inc. (PMI) decreased by 70% to $3.89 - Fusemachines Inc. Common stock (FUSE) down by 17% to $3.29 - American Rebel Holdings, Inc. (AREB) fell by 16% to $3.14 - Armata Pharmaceuticals, Inc. (ARMP) down by 13% to $6.16 - Coya Therapeutics, Inc. (COYA) decreased by 13% to $6.01 - Deckers Outdoor Corporation (DECK) down by 12% to $90.00 - Safe & Green Holdings Corp. (SGBX) fell by 12% to $2.58 - Beasley Broadcast Group, Inc. (BBGI) decreased by 8% to $5.55 - Booz Allen Hamilton Holding Corporation (BAH) down by 7% to $92.73 - Brera Holdings PLC (SLMT) decreased by 6% to $10.67 [4]

Core Viewpoint - Qualigen Therapeutics Inc. has partnered with BitGo to enhance its cryptocurrency treasury strategy, leading to a significant surge in its stock price during after-hours trading [1][2]. Group 1: Stock Performance - Qualigen shares increased by over 60% in after-hours trading, building on a 5.37% gain during the regular trading session, closing at $3.530 [2][4]. - Year-to-date, the stock has decreased by 16.15%, but recent trends indicate a stronger price momentum in the short and medium term [4]. Group 2: Partnership Details - The partnership with BitGo allows Qualigen to manage a diversified investment across the top 10 cryptocurrencies, utilizing BitGo's over-the-counter desk [3]. - BitGo will provide custody and liquidity services for Qualigen's digital assets, ensuring they are stored in regulated cold storage with compliance protocols [3]. Group 3: Company Background - Qualigen is majority-owned by Faraday Future Intelligent Electric Inc., indicating a strategic alignment with a company in the electric vehicle sector [3].

Core Insights - Qualigen Therapeutics Inc. has announced a strategic partnership with BitGo to support its C10 treasury strategy, which aims to accumulate a market-cap-weighted basket of the world's top 10 crypto assets, excluding stablecoins [1][4]. Group 1: Partnership Details - The partnership will allow Qualigen to utilize BitGo's comprehensive treasury management services, which include access to deep liquidity and secure custody solutions [2][3]. - BitGo's OTC desk will facilitate efficient investments across a diversified basket of 10 digital assets, marking a significant advancement in Qualigen's treasury strategy [2][4]. Group 2: Security and Compliance - Qualigen's treasury assets will be stored securely in regulated cold storage by BitGo, adhering to high security standards and compliance protocols [3][4]. - BitGo's expertise in digital assets will simplify the complexities associated with institutional digital asset adoption, enabling Qualigen to focus on sustainable growth and digital integration [3][4]. Group 3: Strategic Vision - The partnership reflects Qualigen's commitment to financial resilience and leadership in the evolving digital economy, as stated by Co-CEO Jerry Wang [4]. - The $30 million multi-asset allocation signifies growing enterprise confidence in adopting a digital-first treasury strategy [4].

Core Viewpoint - The recent decline in the crypto market is viewed as a necessary "stress test" rather than a collapse of market fundamentals, providing an opportunity for strategic asset purchases by CXC10 [2][3][5]. Market Analysis - The crypto market experienced a significant deleveraging event, with over $16 billion in positions liquidated, resulting in a loss of nearly $200 billion in total market capitalization [2][3]. - The primary cause of the pullback was excessive leverage and panic selling, exacerbated by geopolitical factors, particularly Trump's tariff threats against China [3][4]. Strategic Response - CXC10 plans to officially launch strategic asset purchases starting next week, capitalizing on the current market conditions to acquire high-quality assets at attractive prices [6][7]. - The company has established necessary infrastructure for asset purchases, including cash settlement and cryptocurrency custody accounts [7]. Investment Framework - The company employs a systematic SMART Investment Framework, focusing on risk management and strategic allocation to navigate market downturns [8][10]. - The investment strategy includes passive defense by tracking the C10 Index and active allocation to top cryptocurrencies based on quantitative analysis [8][9]. Future Plans - CXC10 aims to expand its investment and M&A focus on core blue-chip assets and high-growth projects that have been undervalued during the market correction [12][13]. - The company is also looking to identify startups for strategic mergers and acquisitions to enhance its industry presence [14]. Long-Term Vision - The company maintains a bullish outlook on the long-term crypto market, driven by regulatory compliance, capital inflows, and technological advancements [15][16]. - The mission is to build a Web3 ecosystem that integrates with the real economy, positioning itself to thrive in both bull and bear markets [16].